BM European Value Retail (LON:BME) “Buy” Rating Maintained by Peel Hunt; The Target is GBX 485.00; Alkermes plc (ALKS) Had 8 Bulls

Among 13 analysts covering Alkermes (NASDAQ:ALKS), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Alkermes has $85 highest and $35 lowest target. $64.25’s average target is 12.38% above currents $57.17 stock price. Alkermes had 34 analyst reports since September 1, 2015 according to SRatingsIntel. The rating was maintained by Barclays Capital with “Overweight” on Wednesday, October 7. JP Morgan upgraded Alkermes plc (NASDAQ:ALKS) on Friday, October 21 to “Overweight” rating. Cantor Fitzgerald maintained it with “Hold” rating and $5300 target in Thursday, July 27 report. Jefferies maintained the stock with “Buy” rating in Thursday, August 24 report. The company was maintained on Thursday, January 21 by Leerink Swann. Barclays Capital maintained the shares of ALKS in report on Friday, July 29 with “Overweight” rating. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, July 13 report. The firm has “Buy” rating given on Tuesday, June 6 by Jefferies. The rating was maintained by Jefferies with “Buy” on Friday, October 21. On Tuesday, July 26 the stock rating was upgraded by Cowen & Co to “Market Perform”. See Alkermes plc (NASDAQ:ALKS) latest ratings:

28/11/2017 Broker: Credit Suisse Rating: Buy New Target: $66.0 Maintain
27/10/2017 Broker: Cowen & Co Rating: Buy New Target: $63.0 Maintain
27/10/2017 Broker: Credit Suisse Rating: Outperform Old Target: $70 New Target: $66 Maintain
27/10/2017 Broker: UBS Rating: Hold New Target: $54.0
26/10/2017 Broker: Citigroup Rating: Hold New Target: $62.0
26/10/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $53.0 Maintain
20/10/2017 Broker: Mizuho Rating: Buy New Target: $81.0 Maintain
16/10/2017 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
26/09/2017 Broker: Jefferies Rating: Buy New Target: $69.0 Maintain
24/08/2017 Broker: Jefferies Rating: Buy New Target: $69.0 Maintain

London: In an analyst report shared with investors and clients on 1 February, Peel Hunt reconfirmed their “Buy” rating on shares of BM European Value Retail (LON:BME). They currently have a GBX 485.00 price target on the firm. Peel Hunt’s target suggests a potential upside of 14.85% from the company’s last close price.

Among 18 analysts covering BM European Value Retail (LON:BME), 14 have Buy rating, 2 Sell and 2 Hold. Therefore 78% are positive. BM European Value Retail has GBX 485 highest and GBX 190 lowest target. GBX 393.89’s average target is -6.73% below currents GBX 422.3 stock price. BM European Value Retail had 184 analyst reports since August 7, 2015 according to SRatingsIntel. Deutsche Bank maintained B&M European Value Retail S.A. (LON:BME) on Wednesday, June 7 with “Buy” rating. Goldman Sachs upgraded B&M European Value Retail S.A. (LON:BME) rating on Friday, July 14. Goldman Sachs has “Buy” rating and GBX 400 target. The firm has “Buy” rating given on Wednesday, March 30 by Jefferies. Haitong Securities maintained it with “Sell” rating and GBX 190 target in Thursday, January 5 report. Numis Securities maintained the shares of BME in report on Thursday, May 25 with “Add” rating. The firm earned “Buy” rating on Monday, February 1 by Deutsche Bank. The stock has “Buy” rating by Jefferies on Wednesday, November 16. The stock of B&M European Value Retail S.A. (LON:BME) has “Outperform” rating given on Monday, January 15 by Credit Suisse. Liberum Capital maintained B&M European Value Retail S.A. (LON:BME) on Wednesday, January 10 with “Buy” rating. The firm has “Buy” rating by Peel Hunt given on Thursday, December 17.

Investors sentiment decreased to 1.63 in 2017 Q3. Its down 0.12, from 1.75 in 2017Q2. It fall, as 1 investors sold B&M European Value Retail S.A. shares while 7 reduced holdings. 2 funds opened positions while 11 raised stakes. 1.21 million shares or 2.12% more from 1.18 million shares in 2017Q2 were reported. Cordasco Financial Net owns 750 shares. Wells Fargo And Company Mn has 0% invested in B&M European Value Retail S.A. (LON:BME) for 42,629 shares. Bb&T Secs Ltd invested in 0% or 10,019 shares. Royal Bankshares Of Canada, a Ontario – Canada-based fund reported 53,863 shares. Natl Bank Of America De holds 762,785 shares or 0% of its portfolio. 1St Source Commercial Bank holds 7,359 shares or 0.02% of its portfolio. Invesco Ltd invested in 0% or 49,958 shares. Reilly Financial Advisors Limited Liability Corporation reported 710 shares. Planning Corp has 0.07% invested in B&M European Value Retail S.A. (LON:BME) for 9,600 shares. Stratos Wealth Prtnrs Ltd holds 0.01% or 6,975 shares in its portfolio. First Allied Advisory Services Inc stated it has 0.05% in B&M European Value Retail S.A. (LON:BME). Arete Wealth Advisors Llc reported 0.24% stake. Advisory Serv Network Limited Liability Corp owns 330 shares or 0% of their US portfolio. Cetera Advisor Net Limited Company stated it has 13,553 shares or 0.02% of all its holdings. The Florida-based Raymond James & has invested 0% in B&M European Value Retail S.A. (LON:BME).

The stock increased 1.54% or GBX 6.4 during the last trading session, reaching GBX 422.3. About 352,130 shares traded. B&M European Value Retail S.A. (LON:BME) has 0.00% since February 1, 2017 and is . It has underperformed by 16.70% the S&P500.

B&M European Value Retail S.A. operates as a general merchandise value retailer in the United Kingdom and Germany. The company has market cap of 4.23 billion GBP. The Company’s stores offer products in various categories, such as home furnishings and adornments, electricals, toys, clothing and footwear products, household goods, toiletries, foods, confectioneries, soft drinks, alcohol, Halloween and Christmas goods, giftware, stationery and crafts, pet care products, DIY and decorating products, and travel accessories, as well as gardening, outdoor, and leisure products. It has a 27.6 P/E ratio. The firm operates approximately 537 stores under the B&M brand in the United Kingdom; and 75 stores under the Jawoll brand in Germany.

Investors sentiment decreased to 1.04 in 2017 Q3. Its down 0.08, from 1.12 in 2017Q2. It fall, as 32 investors sold Alkermes plc shares while 64 reduced holdings. 32 funds opened positions while 68 raised stakes. 144.69 million shares or 1.07% more from 143.16 million shares in 2017Q2 were reported. Quantbot Technology L P has 0.01% invested in Alkermes plc (NASDAQ:ALKS) for 2,490 shares. Creative Planning holds 17,877 shares or 0% of its portfolio. Canada Pension Plan Board has invested 0.01% in Alkermes plc (NASDAQ:ALKS). Tortoise Inv Mgmt has 478 shares. Fiera Corporation owns 0.15% invested in Alkermes plc (NASDAQ:ALKS) for 636,803 shares. Granahan Inv Mngmt Ma stated it has 0.43% of its portfolio in Alkermes plc (NASDAQ:ALKS). Pacad invested 0% of its portfolio in Alkermes plc (NASDAQ:ALKS). Utah Retirement owns 0.03% invested in Alkermes plc (NASDAQ:ALKS) for 27,900 shares. Fmr Ltd Liability holds 23.05M shares or 0.14% of its portfolio. 48,800 are owned by Spark Mgmt Llc. Van Eck Assoc Corporation owns 261,551 shares. Parametric Port Associate Lc owns 130,022 shares. Daiwa Sb Invests, a Japan-based fund reported 2,865 shares. Northern Trust invested in 0.01% or 858,303 shares. State Street holds 0.02% in Alkermes plc (NASDAQ:ALKS) or 4.37M shares.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $8.79 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

The stock decreased 0.21% or $0.12 during the last trading session, reaching $57.17. About 1.05M shares traded or 14.29% up from the average. Alkermes plc (NASDAQ:ALKS) has risen 47.50% since February 1, 2017 and is uptrending. It has outperformed by 30.80% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: